Neurofascin 155 IgG4 Antibody Test
Test in Focus
Mayo Clinic’s new neurofascin 155 IgG4 antibody (NF155) test is the first commercially available test in the U.S. to use flow cytometry to detect for antibody markers associated with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). In this "Test in Focus" episode of the "Answers From the Lab" podcast, John Mills, Ph.D., explains how the testing methodology used in the assay enables increased specificity to identify NF155 antibodies and confirm diagnosis of the rare, progressive illness.
“It’s really important for clinicians to recognize that while there may be other tests that they have access to, they may be testing for pan IgG antibodies or even IgM antibodies where there's not nearly the same extent of specificity, nor do they really define that patient group, as well as those with IgG4 antibodies,” Dr. Mills says. “In the case of the neurofascin 155 IgG4 antibody test, it is particularly critical to have a very high clinical specificity assay…in order to make sure that the test has a high positive predictive value.”
Listen to learn more about how NF155 antibody testing can improve outcomes for patients with NF155 IgG4-associated CIDP, who typically present earlier, with more severity, and require more aggressive therapies to treat the condition than classical CIDP patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluating patients with an underlying demyelinating neuropathy
Diagnosis of a neurofascin-155 IgG4 mediated neuropathy
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.